Women's Health Licensing Deal Calculator —
benchmark your deal in 60 seconds
Phase 2 deals median ~$30M upfront, ~$400M total. Endometriosis and menopause programs are commanding 2x premiums. Built on 1,900+ verified biopharma transactions across 12 therapeutic areas.
Women's Health deal benchmarks at a glance
Median deal terms for women's health licensing transactions, by development phase. Data current as of 2026.
| Phase | Median Upfront | Median Total Value | Median Royalty (Tiered) |
|---|---|---|---|
| Preclinical | $22M | $350M | 3–7% |
| Phase 1 | $60M | $550M | 5–10% |
| Phase 2 | $150M | $1.2B | 7–14% |
| Phase 3 | $380M | $2.2B | 10–18% |
Source: Ambrosia Benchmarker dataset, 1,900+ verified transactions (2017–2026). Primary sources: SEC EDGAR 8-K filings, FTC premerger notifications, ClinicalTrials.gov.
Recent comparable deals
- Astellas–Iveric (non-hormonal menopause)
- Sumitovant–Myovant ($1.7B)
- Daré Bioscience platform deals
Why Women's Health is priced this way
Long-underfunded space seeing a renaissance with non-hormonal menopause therapies (NK3 antagonists), endometriosis, and contraception innovation.
Try it live
Run a Women's Health deal scenario
Pick your phase, modality, and indication. Get instant benchmark ranges — no signup needed to start.
Quick Benchmark
Live data from 1,900+ deals. Select your parameters:
Women's Health licensing — frequently asked
What is the median upfront payment for a Women's Health licensing deal?
How are Women's Health deal milestones structured?
What royalty rates are typical for Women's Health licensing?
Is there a free Women's Health deal calculator?
How does Women's Health licensing compare to other therapeutic areas?
7-Day Free Trial · No Promo Code
Run unlimited women's health deals — Pro.
Monte Carlo sensitivity, partner matching across 850+ companies, scenario comparison (Bear/Base/Bull rNPV), and board-ready PDF reports. Free for 7 days. Cancel anytime.
Then $299/month · No charge during trial · Cancel anytime